Vertaling van "access to medicines " (Nederlands → Frans) :

Treatments worth USD 1.5 billion were contributed through Novartis access-to-medicine programs in 2009, reaching 79.5 million patients in need.
En 2009, Novartis a fourni pour USD 1,5 milliard de traitements par l’intermédiaire de ses programmes d’accès aux médicaments qui ont atteint 79,5 millions de patients dans le besoin.

Access-to-medicine programs including medication for malaria and leprosy reach 80 million patients in 2009 with contributions valued at USD 1.5 billion, or 3% of sales
Les programmes d’accès aux médicaments, qui comprennent des traitements contre le paludisme et la lèpre ont touché 80 millions de malades en 2009 avec des contributions s’élevant à USD 1,5 milliard soit 3% des ventes

However, it is also important for the population of these countries to have access to medicines of the same quality as those on the European market.
However, it is also important for the population of these countries to have access to medicines of the same quality as those on the European market.

“This effort builds on the ongoing work of many partners committed to improving the lives of the 1 billion people affected by NTDs, most of whom are among the world’s poorest. “At Pfizer, we are working to combat NTDs by collaborating on drug development, broadening access to medicines and strengthening health care delivery for underserved people.
“At Pfizer, we are working to combat NTDs by collaborating on drug development, broadening access to medicines and strengthening health care delivery for underserved people.

How can we provide or improve access to our medicines, for people in both developing and developed nations?
Comment donner ou améliorer l’accès à nos médicaments, autant dans les pays développés qu’en voie de développement ?

In this context the FAMHP supports provision of pharmacotherapeutic information to care providers and has concluded partnerships with independent organisations providing objective information about medicines (for instance the Belgian Centre for Pharmacotherapeutic Information – BCFI-CBIP and Project Farmaka, not-for-profit organisations). This process needs to take into consideration the expectations of healthcare professionals in terms of information content on the one hand, and the ease of access and consultation of the data on the other.
In this context the FAMHP supports provision of pharmacotherapeutic information to care providers and has concluded partnerships with independent organisations providing objective information about medicines (for instance the Belgian Centre for Pharmacotherapeutic Information – BCFI-CBIP and Project Farmaka, not-for-profit organisations). This process needs to take into consideration the expectations of healthcare professionals in terms of information content on the one hand, and the ease of access and consultation of the data on the other.

To promote the proper use of a medicine, all relevant parties need to have objective, appropriate, up-todate and readily accessible information.
To promote the proper use of a medicine, all relevant parties need to have objective, appropriate, up-todate and readily accessible information.

The FAMHP and the BUM department in particular ensures that all parties have access to such information, so that medicines can be used rationally and safely.
The FAMHP and the BUM department in particular ensures that all parties have access to such information, so that medicines can be used rationally and safely.

While close to 95% of the items on the World Health Organization’s (WHO) list of essential medicines are available at reduced, off-patent prices, more than a third of the world’s population still has no access to them.
Un seul exemple illustre ce phénomène : à l’heure actuelle, un tiers de la population mondiale reste privée des traitements médicaux de base, alors que près de 95% des articles placés par l’OMS sur sa liste des médicaments essentiels sont disponibles hors brevets, à des prix réduits.

Sandoz completed in September the acquisition of EBEWE Pharma’s specialty generics injectables business for EUR 0.8 billion (USD 1.2 billion), creating a new global growth platform and improving access to oncology medicines.
Sandoz a terminé en septembre l’acquisition pour EUR 0,8 milliard (USD 1,2 milliard) du secteur d’EBEWE Pharma spécialisé dans les génériques injectables, créant ainsi une nouvelle plateforme mondiale de croissance et améliorant l’accès des malades à des médicaments contre le cancer.